Jacobs Levy Equity Management’s ResMed RMD Stock Holding History

Jacobs Levy Equity Management’s Portfolio RMD Stock Details RMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-11,405	Closed	-$2.94M	–	1095
2025 Q2	$2.94M	Buy	+11,405	New	+$2.72M	0.01%	553
2023 Q4	–	Sell	-11,100	Closed	-$1.64M	–	1065
2023 Q3	$1.64M	Buy	+11,100	New	+$2.01M	0.01%	595
2019 Q4	–	Sell	-125,934	Closed	-$17M	–	1056
2019 Q3	$17M	Sell	125,934 -4,716	-4%	-$618K	0.21%	134
2019 Q2	$15.9M	Buy	+130,650	New	+$14.5M	0.22%	118
2016 Q4	–	Sell	-3,470	Closed	-$225K	–	1042
2016 Q3	$225K	Sell	3,470 -59,100	-94%	-$3.93M	﹤0.01%	878
2016 Q2	$3.96M	Sell	62,570 -8,230	-12%	-$485K	0.08%	289
2016 Q1	$4.09M	Buy	+70,800	New	+$4.01M	0.09%	255

Other funds holding RMD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Jacobs Levy Equity Management's RMD Position: Q3 2025 in Review

Jacobs Levy Equity Management sold out of ResMed (RMD) in Q3 2025, closing a stake of 11,405 shares — an estimated $2.94M sold.

Jacobs Levy Equity Management first reported a position in RMD in Q1 2016 and held it in 7 quarters. The position peaked at $17M in Q3 2019. 949 funds tracked by Wall St. Rank hold RMD as of Q3 2025.

Jacobs Levy Equity Management reported no remaining ResMed position as of Q3 2025 after selling out during the quarter.
Jacobs Levy Equity Management sold 11,405 ResMed shares in Q3 2025, an estimated $2.94M.
Jacobs Levy Equity Management first reported a position in ResMed in Q1 2016 and held it in 7 quarters.
Jacobs Levy Equity Management's ResMed position peaked at $17M in Q3 2019.
949 funds tracked by Wall St. Rank held ResMed as of Q3 2025.

Based on Jacobs Levy Equity Management's 13F filing for Q3 2025, filed 17 Nov 2025.